NEJM Volume 394, Issue 9: February 26, 2026 – Medical Research

The New England Journal of Medicine published research on February 26, 2026, exploring a potential link between cerebral folate deficiency, autism spectrum disorder, and the use of leucovorin, a form of folic acid. The study, appearing in Volume 394, Issue 9, pages 833-835, details findings from a small cohort of patients and suggests a possible avenue for further investigation into the underlying causes of autism and potential therapeutic interventions. This research doesn’t establish a causal relationship, but it adds to a growing body of work examining the role of folate metabolism in neurodevelopmental conditions.

Understanding Cerebral Folate Deficiency

Cerebral folate deficiency (CFD) is a rare condition where the brain doesn’t receive enough folate, a B vitamin crucial for many bodily functions, including DNA synthesis and cell growth. Unlike general folate deficiency, which can often be addressed with dietary changes or oral supplements, CFD involves a problem with the transport of folate into the cerebrospinal fluid, which bathes the brain and spinal cord. This transport relies on a protein called the folate receptor alpha. Mutations in the gene encoding this receptor can disrupt folate transport, leading to CFD. The New England Journal of Medicine is a leading source for research on rare conditions like this.

Symptoms of CFD can vary widely, but often include developmental delays, movement disorders, intellectual disability, and behavioral problems. Diagnosis can be challenging, requiring specialized testing of cerebrospinal fluid to measure folate levels. It’s important to note that CFD is distinct from, and much rarer than, simple folate deficiency caused by inadequate dietary intake.

The Autism Connection and Leucovorin’s Role

The recent study published in the NEJM focused on individuals with autism who also exhibited signs of CFD. Researchers investigated whether administering leucovorin – a reduced form of folic acid that can bypass the impaired folate transport system – could improve folate levels in the cerebrospinal fluid and potentially alleviate some of the associated symptoms. Leucovorin is sometimes used to counteract the effects of certain chemotherapy drugs, and it’s also approved for treating folate deficiency caused by specific medical conditions.

The study involved a small number of participants, and the findings are preliminary. However, the researchers observed that leucovorin treatment appeared to increase folate levels in the cerebrospinal fluid of some patients. Importantly, the study did not demonstrate a clear improvement in core autism symptoms. Instead, the focus was on biochemical markers and, in some cases, improvements in secondary symptoms like seizures or sleep disturbances. The researchers emphasize that this is not a cure for autism, and further research is needed to determine whether leucovorin has any meaningful clinical benefit for individuals with both CFD and autism.

Evidence and Limitations of the Study

The study’s design involved a careful assessment of folate levels in both blood and cerebrospinal fluid, along with neurological and behavioral evaluations of the participants. Researchers used lumbar punctures to obtain cerebrospinal fluid samples, a procedure that carries some inherent risks, although these are generally minimal when performed by experienced clinicians. The study’s primary endpoint was the change in cerebrospinal fluid folate levels following leucovorin administration. Secondary endpoints included assessments of neurological function and behavior.

A significant limitation of the study is its small sample size. With only a limited number of participants, it’s difficult to draw firm conclusions about the effectiveness of leucovorin. The study also lacked a control group, meaning there was no comparison to a group of individuals with autism who did not receive leucovorin. This makes it challenging to determine whether any observed improvements were due to the treatment itself or to other factors. The study did not investigate the long-term effects of leucovorin treatment, and the optimal dosage and duration of therapy remain unknown. The authors acknowledge these limitations and call for larger, well-controlled clinical trials to confirm their findings.

What Does This Mean for Individuals and Families?

This research does not suggest that all individuals with autism should receive leucovorin. It specifically focuses on a subset of individuals who also have evidence of cerebral folate deficiency. It’s crucial to emphasize that autism is a complex neurodevelopmental condition with a wide range of causes, and there is no single treatment that works for everyone.

If a child has been diagnosed with autism and is experiencing developmental delays or other symptoms that might suggest CFD, it’s important to discuss this possibility with a qualified clinician. Testing for CFD involves measuring folate levels in cerebrospinal fluid, which requires a specialist’s expertise. Press releases regarding this research highlight the need for further investigation.

Public Health Implications and Future Research

The findings from this study underscore the importance of considering metabolic factors in the evaluation of autism. While genetic factors are known to play a significant role in autism, it’s increasingly recognized that environmental and metabolic factors may also contribute to the development of the condition. Further research is needed to identify individuals who might benefit from targeted interventions aimed at improving folate metabolism.

What comes next involves several key steps. Larger, randomized controlled trials are essential to confirm the findings of this initial study and to determine the optimal dosage and duration of leucovorin treatment. Researchers also need to investigate the underlying mechanisms by which leucovorin might exert its effects, and to identify biomarkers that can predict which individuals are most likely to respond to therapy. Studies are needed to assess the long-term safety and efficacy of leucovorin in this population. The National Institutes of Health (NIH) is a key funding source for autism research and may support future studies in this area. The New England Journal of Medicine will likely continue to publish research on this topic as it evolves.

Ongoing surveillance of folate levels in individuals with autism, particularly those with unexplained developmental delays, may help to identify those who could potentially benefit from further evaluation for CFD. A better understanding of the interplay between folate metabolism and neurodevelopmental disorders could lead to more effective strategies for prevention and treatment.